Clementia to Present at the Evercore ISI HealthCONx Conference
21 Novembre 2018 - 12:30PM
Clementia Pharmaceuticals Inc. (Nasdaq: CMTA), a
clinical-stage biopharmaceutical company innovating treatments for
people with ultra-rare bone disorders and other diseases, today
announced that Clarissa Desjardins, Ph.D., chief executive officer
and founder of Clementia, will present at the Evercore ISI
HealthCONx Conference on Wednesday, November 28, 2018 at 10:15 a.m.
ET in Boston.
A webcast of the presentation will be available
in the Investor Relations section of the company's website at
www.clementiapharma.com. The replay of the webcast will be
available for 30 days following the call.
About Clementia Pharmaceuticals
Inc.
Clementia is a clinical-stage company innovating
treatments for people with ultra-rare bone disorders and other
diseases with high medical need. The company is preparing for a
2019 NDA submission to the FDA to seek approval of its lead product
candidate, palovarotene, a novel RARγ agonist, for the prevention
of heterotopic ossification (HO) associated with flare up symptoms
in patients with fibrodysplasia ossificans progressiva (FOP). The
ongoing Phase 3 MOVE Trial is evaluating an additional dosing
regimen of palovarotene for the treatment of FOP. Palovarotene is
also in a Phase 2 trial, the MO-Ped Trial, for the treatment of
multiple osteochondromas (MO, also known as multiple hereditary
exostoses, or MHE). In addition, Clementia has commenced a Phase 1
trial for an eye drop formulation of palovarotene for the potential
treatment of dry eye disease and is also investigating other
conditions that may benefit from RARγ therapy. For more
information, please visit www.clementiapharma.com and connect with
us on Twitter @ClementiaPharma.
Investor/Media Contact:Joseph
WalewiczClementia Pharmaceuticals Inc.+1-514-940-1080
Chelcie ListerTHRUST Strategic
Communications+1-910-777-3049
Clementia Pharmaceuticals Inc. (NASDAQ:CMTA)
Graphique Historique de l'Action
De Mai 2024 à Juin 2024
Clementia Pharmaceuticals Inc. (NASDAQ:CMTA)
Graphique Historique de l'Action
De Juin 2023 à Juin 2024
Real-Time news about Clementia Pharmaceuticals Inc. (NASDAQ): 0 recent articles
Plus d'articles sur